{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.2"}]}],"title":"ACR20 Week 48: Maintained 24 weeks (n=1937)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.0"}]}],"title":"ACR20 Week 96: Maintained 24 weeks (n=1745)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.0"}]}],"title":"ACR20 Week 96: Maintained 48 weeks (n=1745)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.3"}]}],"title":"ACR20 Week 144: Maintained 24 weeks (n=1615)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.7"}]}],"title":"ACR20 Week 144: Maintained 48 weeks (n=1615)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.6"}]}],"title":"ACR20 Week 144: Maintained 96 weeks (n=1615)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0"}]}],"title":"ACR20 Week 192: Maintained 24 weeks (n=1514)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.3"}]}],"title":"ACR20 Week 192: Maintained 48 weeks (n=1514)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.3"}]}],"title":"ACR20 Week 192: Maintained 96 weeks (n=1514)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.8"}]}],"title":"ACR20 Week 192: Maintained 144 weeks (n=1514)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.0"}]}],"title":"ACR20 Week 264: Maintained 24 weeks (n=1358)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.7"}]}],"title":"ACR20 Week 264: Maintained 48 weeks (n=1358)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.2"}]}],"title":"ACR20 Week 264: Maintained 96 weeks (n=1358)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.7"}]}],"title":"ACR20 Week 264: Maintained 144 weeks (n=1358)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.6"}]}],"title":"ACR20 Week 264: Maintained 192 weeks (n=1358)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.7"}]}],"title":"ACR50 Week 48: Maintained 24 weeks (n=1937)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.0"}]}],"title":"ACR50 Week 96: Maintained 24 weeks (n=1745)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.8"}]}],"title":"ACR50 Week 96: Maintained 48 weeks (n=1745)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.9"}]}],"title":"ACR50 Week 144: Maintained 24 weeks (n=1615)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.4"}]}],"title":"ACR50 Week 144: Maintained 48 weeks (n=1615)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.1"}]}],"title":"ACR50 Week 144: Maintained 96 weeks (n=1615)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.8"}]}],"title":"ACR50 Week 192: Maintained 24 weeks (n=1514)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.0"}]}],"title":"ACR50 Week 192: Maintained 48 weeks (n=1514)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.7"}]}],"title":"ACR50 Week 192: Maintained 96 weeks (n=1514)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.9"}]}],"title":"ACR50 Week 192: Maintained 144 weeks (n=1514)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.3"}]}],"title":"ACR50 Week 264: Maintained 24 weeks (n=1358)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.7"}]}],"title":"ACR50 Week 264: Maintained 48 weeks (n=1358)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.6"}]}],"title":"ACR50 Week 264: Maintained 96 weeks (n=1358)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.7"}]}],"title":"ACR50 Week 264: Maintained 144 weeks (n=1358)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6"}]}],"title":"ACR50 Week 264: Maintained 192 weeks (n=1358)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5"}]}],"title":"ACR70 Week 48: Maintained 24 weeks (n=1937)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2"}]}],"title":"ACR70 Week 96: Maintained 24 weeks (n=1745)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2"}]}],"title":"ACR70 Week 96: Maintained 48 weeks (n=1745)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9"}]}],"title":"ACR70 Week 144: Maintained 4 weeks (n=1615)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0"}]}],"title":"ACR70 Week 144: Maintained 48 weeks (n=1615)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7"}]}],"title":"ACR70 Week 144: Maintained 96 weeks (n=1615)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.9"}]}],"title":"ACR70 Week 192: Maintained 24 weeks (n=1514)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6"}]}],"title":"ACR70 Week 192: Maintained 48 weeks (n=1514)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4"}]}],"title":"ACR70 Week 192: Maintained 96 weeks (n=1514)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3"}]}],"title":"ACR70 Week 192: Maintained 144 weeks (n=1514)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.9"}]}],"title":"ACR70 Week 264: Maintained 24 weeks (n=1358)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7"}]}],"title":"ACR70 Week 264: Maintained 48 weeks (n=1358)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4"}]}],"title":"ACR70 Week 264: Maintained 96 weeks (n=1358)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0"}]}],"title":"ACR70 Week 264: Maintained 144 weeks (n=1358)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7"}]}],"title":"ACR70 Week 264: Maintained 192 weeks (n=1358)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2067"}],"units":"Participants"}],"description":"Improvement must be seen in tender (68 assessed joints) and swollen joint counts (66 assessed joints) and in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, the left end of the scale \"no disease activity\" \\[symptom-free and no arthritis symptoms\\], right end of the scale \"maximum disease activity\"); patient assessment of pain in the previous 24 hours on a VAS (left end of the scale \"no pain\", right end of the scale \"unbearable pain\"); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and erythrocyte sedimentation rate.","groups":[{"description":"Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.","id":"OG000","title":"Tocilizumab"}],"paramType":"NUMBER","populationDescription":"All-exposure population: All participants who entered this study and received at least 1 dose of tocilizumab in either this extension study or in a core study. Only participants with available data were included in the analysis.","timeFrame":"Baseline to Week 264","title":"Percentage of Participants Who Maintained an Improvement of at Least 20%, 50%, or 70% in the American College of Rheumatology (ACR) Score (ACR20/50/70) Consecutively for 24, 48, 96, and 264 Weeks at Weeks 48, 96, 144, 192, and 264","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}